Pfizer partners with healthtech company on AI-powered cardiovascular disease detection

Related Articles
Pfizer to partner with Mayo Clinic spinoff on early cardiac amyloidosis detection
Medtech Dive: Anumana, a health technology startup spun out of Mayo Clinic, entered a multi-year agreement with Pfizer to develop an algorithm to detect cardiac amyloidosis, a serious heart condition.…December 16, 2022
Migraine with aura identified as independent risk factor for A-fib
Medical Xpress: Patients with migraine with aura (MwA) have significantly higher artificial intelligence-enabled electrocardiogram (AI-ECG) atrial fibrillation (AF) prediction model output, according to a study from Mayo Clinic published online…August 03, 2022
Building sEHR-BERT: A Custom Language Model for Structured Electronic Health Records – Adapting transformer architecture for the unique challenges of medical coding and structured health data
Why Standard BERT Isn't Enough for Structured EHRs BERT revolutionized natural language processing, but electronic health records (EHRs) present unique challenges that standard language models weren't designed to handle. While BERT…January 22, 2026
Pfizer, Anumana team up to develop AI algorithm for cardiac amyloidosis detection
Mobi Health News: Anumana, a joint venture between EHR data company nference and the Mayo Clinic, entered into a multiyear partnership with Pfizer to develop an AI-based tool for the…December 16, 2022


